JP2020530993A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530993A5
JP2020530993A5 JP2020505194A JP2020505194A JP2020530993A5 JP 2020530993 A5 JP2020530993 A5 JP 2020530993A5 JP 2020505194 A JP2020505194 A JP 2020505194A JP 2020505194 A JP2020505194 A JP 2020505194A JP 2020530993 A5 JP2020530993 A5 JP 2020530993A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid sequence
cell
expressed
noi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020505194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530993A (ja
Filing date
Publication date
Priority claimed from GBGB1712407.4A external-priority patent/GB201712407D0/en
Priority claimed from GBGB1806372.7A external-priority patent/GB201806372D0/en
Application filed filed Critical
Priority claimed from PCT/GB2018/052204 external-priority patent/WO2019025800A1/en
Publication of JP2020530993A publication Critical patent/JP2020530993A/ja
Publication of JP2020530993A5 publication Critical patent/JP2020530993A5/ja
Priority to JP2023057340A priority Critical patent/JP2023076572A/ja
Pending legal-status Critical Current

Links

JP2020505194A 2017-08-02 2018-08-01 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞 Pending JP2020530993A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023057340A JP2023076572A (ja) 2017-08-02 2023-03-31 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1712407.4A GB201712407D0 (en) 2017-08-02 2017-08-02 Cell
GB1712407.4 2017-08-02
GB1806372.7 2018-04-19
GBGB1806372.7A GB201806372D0 (en) 2018-04-19 2018-04-19 Cell
PCT/GB2018/052204 WO2019025800A1 (en) 2017-08-02 2018-08-01 CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023057340A Division JP2023076572A (ja) 2017-08-02 2023-03-31 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞

Publications (2)

Publication Number Publication Date
JP2020530993A JP2020530993A (ja) 2020-11-05
JP2020530993A5 true JP2020530993A5 (enExample) 2021-07-26

Family

ID=63371717

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020505194A Pending JP2020530993A (ja) 2017-08-02 2018-08-01 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞
JP2023057340A Pending JP2023076572A (ja) 2017-08-02 2023-03-31 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023057340A Pending JP2023076572A (ja) 2017-08-02 2023-03-31 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞

Country Status (7)

Country Link
US (1) US20210130775A1 (enExample)
EP (1) EP3662055A1 (enExample)
JP (2) JP2020530993A (enExample)
CN (1) CN111164203A (enExample)
AU (1) AU2018311345A1 (enExample)
CA (1) CA3071495A1 (enExample)
WO (1) WO2019025800A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220056407A1 (en) * 2018-12-14 2022-02-24 Autolus Limited Cell
US11969443B2 (en) * 2019-03-06 2024-04-30 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
CN113543792A (zh) 2019-03-08 2021-10-22 奥托路斯有限公司 包含工程化嵌合抗原受体和car调节剂的组合物和方法
WO2021028359A1 (en) * 2019-08-09 2021-02-18 Sangamo Therapeutics France Controlled expression of chimeric antigen receptors in t cells
EP4017510A4 (en) * 2019-08-20 2023-11-22 Senti Biosciences, Inc. CHIMERIC INHIBITOR RECEPTOR
AU2020379848A1 (en) * 2019-11-06 2022-05-19 Baylor College Of Medicine Method for producing cytotoxic effector memory T cells for T-cell treatment of cancer
US20230304031A1 (en) * 2020-05-11 2023-09-28 Abintus Bio, Inc. Vectors and methods for in vivo transduction
GB202013466D0 (en) * 2020-08-27 2020-10-14 Inst De Medicina Molecular Joaeo Lobo Antunes Genetic construct
EP4455157A1 (en) * 2023-04-27 2024-10-30 Fundacion Publica Andaluza Progreso Y Salud M.P.- Fps Polynuceotide for t cell specific transgene expression
WO2025226608A1 (en) * 2024-04-22 2025-10-30 The Johns Hopkins University Immunotoxin-armored immune effector cells and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030386T2 (en) 2007-01-31 2017-05-29 Yeda Res & Dev Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
US8465743B2 (en) * 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
GB201206559D0 (en) * 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
WO2014055657A1 (en) * 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
LT2958943T (lt) * 2013-02-20 2020-01-27 The Trustees Of The University Of Pennsylvania Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
TWI654206B (zh) * 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
MX377283B (es) * 2013-11-21 2025-03-07 Ucl Business Ltd Célula t o nk que coexpresa un receptor antigénico quimérico (car).
WO2015092024A2 (en) * 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
SG11201606583VA (en) * 2014-03-05 2016-09-29 Ucl Business Plc Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region
US11385233B2 (en) * 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
GB201403972D0 (en) * 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
GB201405845D0 (en) * 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
IL301458A (en) * 2014-12-24 2023-05-01 Autolus Ltd A cell that simultaneously expresses a chimeric antigen receptor (CAR) of 19CD and 22CD
GB201501936D0 (en) * 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503133D0 (en) * 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
GB201504840D0 (en) * 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
GB201507111D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507108D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
MA43344A (fr) * 2015-05-29 2018-04-11 Juno Therapeutics Inc Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées
GB201514874D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Cell
US11098283B2 (en) * 2015-08-25 2021-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cells modified to overexpress c-Myb
US10286092B2 (en) * 2015-08-25 2019-05-14 Ucl Business Plc Detecting a therapeutic cell
WO2017040324A1 (en) * 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
KR20180053744A (ko) * 2015-09-23 2018-05-23 사이토이뮨 테라퓨틱스 엘엘씨 면역 요법을 위한 flt3 유도된 car 세포
GB201518817D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Cell
WO2017075537A1 (en) * 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
GB201519900D0 (en) * 2015-11-11 2015-12-23 Ucl Business Plc Chimeric antigen receptor
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
GB201609604D0 (en) * 2016-06-01 2016-07-13 Ucl Business Plc Cell
GB201610515D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Cell
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
CA2937157A1 (en) * 2016-07-25 2018-01-25 Ucl Business Ltd Protein-based t-cell receptor knockdown
US20180064758A1 (en) * 2016-09-05 2018-03-08 Ucl Business Plc Chimeric antigen receptor
BR112019004629A2 (pt) * 2016-09-08 2019-10-01 Bluebird Bio, Inc. variantes de endonuclease de homing pd-1, composições e métodos de uso
AU2017357649A1 (en) * 2016-11-11 2019-05-23 Autolus Limited Chimeric antigen receptor
GB201621891D0 (en) * 2016-12-21 2017-02-01 Autolus Ltd Transcription system
EP3612568B8 (en) * 2017-04-18 2021-12-08 Autolus Limited Cell
GB201707779D0 (en) * 2017-05-15 2017-06-28 Autolus Ltd Cell
CN110913871B (zh) * 2017-05-17 2024-02-23 西雅图儿童医院（Dba西雅图儿童研究所） 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法
GB201716728D0 (en) * 2017-10-12 2017-11-29 Autolus Ltd Cell
EP3684919A1 (en) * 2017-10-19 2020-07-29 Cellectis Targeted gene integration of nk inhibitors genes for improved immune cells therapy
GB201718697D0 (en) * 2017-11-13 2017-12-27 Autolus Ltd Cell
GB201800298D0 (en) * 2018-01-09 2018-02-21 Autolus Ltd Method
GB201807870D0 (en) * 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
AU2019269118B2 (en) * 2018-05-15 2025-02-27 Autolus Limited Chimeric antigen receptor
GB201807862D0 (en) * 2018-05-15 2018-06-27 Ucl Business Plc Chimeric antigen receptor
FI3856775T3 (fi) * 2018-09-27 2024-12-04 Autolus Ltd Kimeerinen antigeenireseptori
GB201816522D0 (en) * 2018-10-10 2018-11-28 Autolus Ltd Methods and reagents for analysing nucleic acids from single cells
US20220056407A1 (en) * 2018-12-14 2022-02-24 Autolus Limited Cell
CN113543792A (zh) * 2019-03-08 2021-10-22 奥托路斯有限公司 包含工程化嵌合抗原受体和car调节剂的组合物和方法
GB201906202D0 (en) * 2019-05-02 2019-06-19 Autolus Ltd Cell
GB201910651D0 (en) * 2019-07-25 2019-09-11 Autolus Ltd Virus-like particle

Similar Documents

Publication Publication Date Title
Khan et al. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors
Labanieh et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
Sagiv et al. NKG2D ligands mediate immunosurveillance of senescent cells
Nebral et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia
Kudo-Saito et al. CCL2 is critical for immunosuppression to promote cancer metastasis
AU2016283102B2 (en) Chimeric antigen receptors (CARs), compositions and methods of use thereof
BR112021007626A2 (pt) Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d)
JP6546160B2 (ja) 腫瘍細胞による免疫抑制を低下させるための方法および組成物
Su et al. LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs
CN113015744A (zh) 单链嵌合多肽和多链嵌合多肽以及其用途
AU2018268087B2 (en) Compositions and methods for cell targeting therapies
Ito et al. mTOR complex signaling through the SEMA4A–Plexin B2 axis is required for optimal activation and differentiation of CD8+ T cells
JP2023076572A (ja) キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞
RU2017132293A (ru) Химерный белок
CN111246861A (zh) 扩增表达重组受体的细胞的试剂
WO2016038550A1 (en) Inhibition of prmt5 to treat mtap-deficiency-related diseases
Lindner et al. The miR‐15 family reinforces the transition from proliferation to differentiation in pre‐B cells
Birley et al. A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers
CN110461881A (zh) 嵌合抗原受体
Jaeger-Ruckstuhl et al. TNIK signaling imprints CD8+ T cell memory formation early after priming
AU2023354543A1 (en) Compositions and methods for enhancing adoptive t cell therapeutics
Yi et al. L1 cell adhesion molecule induces melanoma cell motility by activation of mitogen-activated protein kinase pathways
Xu et al. Advances in the multi-omics landscape of follicular lymphoma
KR20230143135A (ko) Cd19+, cd20+ 또는 cd22+ 종양 또는 b-세포 유래 자가-면역질환을 치료하기 위한 car t-세포
KR20240090127A (ko) 개선된 면역치료법을 위한 방법 및 조성물